Taiho Oncology names new president
11 January 2018 -

Taiho Oncology, a subsidiary of Taiho Pharmaceuticals, has promoted Timothy Whitten as its new president, it is reported today.

Whitten was senior vice president and chief operating officer. He will continue to report to the firm's departing president, Eric Benn, who will continue in his role as chief executive officer until his retirement on 1 April at which time Whitten will also be named CEO.

In the new role, the president will take responsibility for the firm's corporate, commercial and clinical development-related functions and hold operational responsibility for Taiho Pharma Canada and Taiho Pharma Europe. He joined Taiho Oncology in 2013 as its senior vice president and chief commercial officer to oversee the company's commercial functions. Prior to this, he served pharmaceutical companies including Insmed and BMS.